The estimated Net Worth of Matthew Ros is at least $2.37 Million dollars as of 4 February 2021. Mr. Ros owns over 894 units of Epizyme Inc stock worth over $122,286 and over the last 8 years he sold EPZM stock worth over $165,690. In addition, he makes $2,081,990 as Chief Strategy and Business Officer at Epizyme Inc.
Matthew has made over 8 trades of the Epizyme Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 894 units of EPZM stock worth $10,022 on 4 February 2021.
The largest trade he's ever made was exercising 112,003 units of Epizyme Inc stock on 18 June 2020 worth over $1,060,668. On average, Matthew trades about 8,480 units every 48 days since 2016. As of 4 February 2021 he still owns at least 83,188 units of Epizyme Inc stock.
You can see the complete history of Mr. Ros stock trades at the bottom of the page.
Matthew E. Ros serves as Chief Strategy and Business Officer of the Company. He has served as our Chief Strategy and Business Officer since September 2018 and served as our Chief Operating Officer from May 2016 to September 2018. Prior to joining us, from September 2010 to May 2016, Mr. Ros served in increasing levels of responsibility at Sanofi, a multinational pharmaceutical company, most recently as Chief Operating Officer/Global Head of the Oncology Business unit from December 2014 to May 2016. Prior to that role, Mr. Ros served in the rare disease business of Genzyme, a Sanofi company, where he served as Vice President and Franchise Head of its Pompe disease unit from September 2012 to December 2014, and also served as the Associate Vice President and Iniparib Global Brand Leader in Sanofi’s Oncology Business unit from September 2010 to September 2012. From October 2007 to June 2010, Mr. Ros served at ARIAD Pharmaceuticals, Inc., a global oncology company, most recently as Senior Vice President, Commercial Operations. He started his pharmaceutical career in Bristol-Myers Squibb’s Oncology Division, serving in roles with increasing responsibility from 1990 to 2007. He received a B.S. from the State University of New York, College at Plattsburgh and completed the Executive Education Program in Finance and Accounting for the Non-Financial Manager at Wharton School of the University of Pennsylvania.
As the Chief Strategy and Business Officer of Epizyme Inc, the total compensation of Matthew Ros at Epizyme Inc is $2,081,990. There are 3 executives at Epizyme Inc getting paid more, with Robert Bazemore having the highest compensation of $4,173,620.
Matthew Ros is 53, he's been the Chief Strategy and Business Officer of Epizyme Inc since 2018. There are 13 older and 4 younger executives at Epizyme Inc. The oldest executive at Epizyme Inc is Kenneth Bate, 69, who is the Independent Director.
Matthew's mailing address filed with the SEC is 400 Technology Square, Cambridge, MA 02139, USA.
Over the last 11 years, insiders at Epizyme Inc have traded over $122,255,844 worth of Epizyme Inc stock and bought 45,285,781 units worth $322,885,823 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Peter J Barris. On average, Epizyme Inc executives and independent directors trade stock every 17 days with the average trade being worth of $394,367. The most recent stock trade was executed by Grant C. Bogle on 9 August 2022, trading 1,217,500 units of EPZM stock currently worth $1,704,500.
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..
Epizyme Inc executives and other stock owners filed with the SEC include: